In its latest quarterly filing, iSpecimen Inc. disclosed progress in expanding its iSpecimen Marketplace technology platform and announced a $2.5 million private placement aimed at supporting this growth. The company's marketplace connects healthcare specimen providers with researchers by harmonizing complex biospecimen and patient data for efficient procurement workflows. Despite these operational advancements, iSpecimen remains unprofitable with recurring losses and retains going concern risks. Customer concentration and regulatory compliance continue as material risk factors. The company’s proprietary platform and increasing supplier network form durable competitive moats, but scalability depends on further technological enhancements and broader customer adoption.